Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0IXBOR
ADC Name
CN109310781A ADC-2
Synonyms
CN109310781A_ADC-2
   Click to Show/Hide
Organization
Bayer Pharma AG
Drug Status
Investigative
Indication
In total 1 Indication(s)
Acute myeloid leukemia [ICD11:2A60]
Investigative
Drug-to-Antibody Ratio
3.4
Antibody Name
TPP-6013
  Antibody Info 
Antigen Name
Interleukin-3 receptor subunit alpha (IL3RA)
  Antigen Info 
Payload Name
Undisclosed
Linker Name
CN109310781A ADC-2 linker
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 3 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Inhibitory Concentration (IC50) 
0
nM
CVCL_2119
Adult acute myeloid leukemia
Half Maximal Inhibitory Concentration (IC50) 
0
nM
CVCL_0006
Childhood acute monocytic leukemia
Half Maximal Inhibitory Concentration (IC50) 
300
nM
CVCL_0005
Promyelocytic leukemia
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 3 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 1.21 nM Positive CD123 expression (CD123+++/++)
Method Description
Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.

   Click to Show/Hide
In Vitro Model Adult acute myeloid leukemia MOLM-13 cells CVCL_2119
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 1.60 nM Positive CD123 expression (CD123+++/++)
Method Description
Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.

   Click to Show/Hide
In Vitro Model Childhood acute monocytic leukemia THP-1 cells CVCL_0006
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 300.00 nM Positive CD123 expression (CD123+++/++)
Method Description
Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.

   Click to Show/Hide
In Vitro Model Promyelocytic leukemia NB-4 cells CVCL_0005
References
Ref 1 Specific antibody-drug-conjugate (ADC) with KSP inhibitor and anti-CD123- antibody.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.